



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.com

CIN L85195MP1988PLC004446

Date: -09th September, 2017

**To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai - 400 001
BSE Code: 532878**

**To,
Listing Department,
National Stock Exchange of India Limited.
Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Code: ALPA**

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

This is to inform you that the Board of Directors of the Company at its meeting held today that is on **Saturday 09th September, 2017 at 03.45 P.M. and concluded at 08:30P.M.** at Registered Office of the Company at Indore. The Board inter-alia has approved the following matter:

1. Approval of Standalone Financial Results of the Company for quarter and period ended 30th June,2017.

You are requested to take the same on records.

Thanking you,

Yours Faithfully

For ALPA LABORATORIES LIMITED


Mahendra

**MS Chawla
Director
DIN No.00362058**



**INDEPENDENT AUDITORS REVIEW REPORT ON STANDALONE QUARTERLY FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION, 2015.****To the Board of Directors of ALPA LABORATORIES LIMITED,**

1. We have reviewed the accompanying statement of unaudited financial results ('Statement') of M/s Alpa Laboratories Limited ('the Company') for the quarter ended 30th June, 2017, being submitted by the Company pursuant the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based our review.
2. We conducted our review in accordance with the standard on review Engagement (SRE) 2400 Engagement to Review Financial Statement issued by the Institute of Chartered Accountant of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material statement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than audit. We have not performed an audit and accordingly we do not express an audit opinion.
3. Based on our review conducted as above nothing has come to our attention that cause us to believe that the accompanying statement of unaudited results prepared in accordance with applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 and SEBI circular CIR/CFD/CMD/15/2015 dated 30 November, 2015 and CIR/CFD/AFC/62/2016 dated 5 July 2016 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 including the manner in which in which is to be disclosed, or that it contains any material misstatement.

For & On Behalf of
C.H. Padliya & Co.
Chartered Accountants
FRN No. 003151C

S.C. PADLIYA
M. No. 071666

Place: Indore

Date: This 9th September, 2017

Financial Results for Quarter ended 30th June 2017

(Rs.in lacs)

Particulars	Standalone Results			
	Quarter Ended			Year Ended
	30.06.2017	31.03.2017	30.06.2016	31.03.2017
	Unaudited			Audited
(a) Net sales/income from operations (Net of Excise duty)	1081.56	2088.84	1499.79	6477.23
(b) Other operating income	4.41	21.09	13.43	83.88
1. Total income from operations (net) (a+b)	1085.96	2109.93	1513.22	6,561.11
(c) Cost of materials consumed	697.18	1054.34	974.86	3807.05
(d) Purchases of stock-in-trade	-	-	-	-
(e) Changes in inventories of fin. goods, stock-in-pro. & stock-in-trade	-114.80	282.24	-66.25	52.94
(f) Employee benefits expense	240.35	268.37	185.13	863.67
(g) Depreciation and amortization expense	22.79	20.69	17.62	76.08
(h) Other expenses	234.03	398.28	236.23	1126.91
2. Total expenses (c+d+e+f+g+h)	1079.56	2023.92	1347.60	5926.65
3. Profit/ Loss(-) from operations before other income and finance costs and exceptional items (1-2)	6.41	86.01	165.63	634.46
4. Other income	142.54	223.62	134.80	613.05
5. Profit/ Loss(-) from ordinary activities before finance costs and exceptional items (3+4)	148.95	309.63	300.43	1247.51
6. Finance costs	24.29	27.19	52.82	170.95
7. Profit/ Loss(-) from ordinary activities after finance cost but before exceptional items (5-6)	124.66	282.44	247.61	1076.56
8. Exceptional items	-	-	-	211.53
9. Net Profit/ Loss(-) from ordinary activities before tax (7+/-8)	124.66	282.44	247.61	865.03
10. Tax expense	-	293.00	-	293.00
11. Net Profit/ Loss(-) from ordinary activities after tax (9-10)	124.66	-10.56	247.61	572.03
12. loss from extraordinary activities	-	-	-	-
13. Net Profit & Loss after tax and Extraordinary Items (11+/-12)	124.66	-10.56	247.61	572.03
14. Share of Profit (Loss) of Associates	-	-	-	-
15. Minority Interest (For Consolidated Result Only)	N/A	N/A	N/A	N/A
16. Net Profit & loss After Minority Interest and share of profit/ loss of associates (13+14+15)	124.66	-10.56	247.61	572.03
17. Other Comprehensive Income				
(i) (a) Items that will not be reclassified to profit or loss	-	-	-	-
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	-	-	-	-
18. Total comprehensive income for the period (16+17)	-	-	-	-
19. Paid-up equity share capital (Face Value `10 Each)	2104.06	2104.06	2104.06	2104.06
20. Reserves excluding Revaluation Reserves as per bal. sheet of prev. year	-	-	-	7186.47
21 i Basic and Diluted Earnings per share before extraordinary items (not annualized)	0.59	-0.05	1.18	2.72
22 ii Basic and Diluted Earnings per share after extraordinary items (not annualized)	0.59	-0.05	1.18	2.72

Notes -

- The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.



Mahendra